Edition:
United Kingdom

Adverum Biotechnologies Inc (ADVM.OQ)

ADVM.OQ on NASDAQ Stock Exchange Global Market

5.90USD
25 Apr 2018
Change (% chg)

-- (--)
Prev Close
$5.90
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
186,376
52-wk High
$8.55
52-wk Low
$2.45

Chart for

About

Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE) as well as wet age-related... (more)

Overall

Beta: 3.67
Market Cap(Mil.): $373.04
Shares Outstanding(Mil.): 62.17
Dividend: --
Yield (%): --

Financials

  ADVM.OQ Industry Sector
P/E (TTM): -- 178.44 32.31
EPS (TTM): -1.07 -- --
ROI: -22.11 -0.73 12.97
ROE: -23.01 -2.77 14.84

BRIEF-Adverum Biotechnologies Q4 Loss Per Share $0.32

* ADVERUM BIOTECHNOLOGIES REPORTS FOURTH QUARTER 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

06 Mar 2018

BRIEF-Adverum Biotechnologies Prices $60 Mln Public Offering Of Stock

* ADVERUM BIOTECHNOLOGIES ANNOUNCES PRICING OF $60 MILLION PUBLIC OFFERING OF COMMON STOCK

08 Feb 2018

BRIEF-Adverum Biotechnologies Announces Proposed Public Offering

* ADVERUM BIOTECHNOLOGIES ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

07 Feb 2018

BRIEF-Adverum Biotechnologies Extends Collaboration Agreement With Editas Medicine

* ANNOUNCES EXTENSION OF ITS COLLABORATION AGREEMENT WITH EDITAS MEDICINE INC

25 Jan 2018

BRIEF-Adverum Biotechnologies Provides 2018 Outlook

* ADVERUM BIOTECHNOLOGIES INC - ADVERUM'S CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE $186.6 MILLION AS OF SEPTEMBER 30, 2017.

04 Jan 2018

BRIEF-Highbridge Capital Reports 5.55 Pct Passive Stake In Adverum Biotechnologies

* HIGHBRIDGE CAPITAL MANAGEMENT LLC REPORTS 5.55 PERCENT PASSIVE STAKE IN ADVERUM BIOTECHNOLOGIES INC AS OF DECEMBER 5 - SEC FILING Source text for Eikon: (http://bit.ly/2iwSEnw) Further company coverage:

06 Dec 2017

BRIEF-Adverum Begins Patient Enrollment In Advance Phase 1/2 Clinical Trial

* ADVERUM BIOTECHNOLOGIES BEGINS PATIENT ENROLLMENT IN THE ADVANCE PHASE 1/2 CLINICAL TRIAL FOR A1AT DEFICIENCY

05 Dec 2017

BRIEF-‍Adage Capital Partners Reports A 5.55 Percent Passive Stake In Adverum Biotechnologies As Of Nov 17, 2017

* ‍ADAGE CAPITAL PARTNERS GP, L.L.C REPORTS A 5.55 PERCENT PASSIVE STAKE IN ADVERUM BIOTECHNOLOGIES INC AS OF NOVEMBER 17, 2017 - SEC FILING​ Source text: (http://bit.ly/2hXgpom) Further company coverage:

27 Nov 2017

BRIEF-Adverum Biotechnologies posts Q3 loss of $0.32 per share

* Adverum biotechnologies reports third quarter 2017 financial results and provides corporate update

08 Nov 2017

Earnings vs. Estimates